Icon

CEFTIN (nda050605)- (EQ 125MG BASE,EQ 250MG BASE,EQ 500MG BASE)

CEFUROXIME AXETIL GLAXOSMITHKLINE
EQ 125MG BASE,EQ 250MG BASE,EQ 500MG BASE
No No
Expired Expired
None None
None No
CEFTIN is a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria:  Pharyngitis/tonsillitis (adults and pediatric patients)  Acute bacterial otitis media (pediatric patients)  Acute bacterial maxillary sinusitis (adults and pediatric patients)  Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older)  Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older)  Uncomplicated urinary tract infections (adults and pediatric patients 13 years and older)  Uncomplicated gonorrhea (adults and pediatric patients 13 years and older)  Early Lyme disease (adults and pediatric patients 13 years and older)  Impetigo (pediatric patients)
6 0 3
Total Other Developers None
Drugs with Suitability No
EQ 125MG BASE ** ** - - -
EQ 250MG BASE ** ** - - 3
EQ 500MG BASE ** ** - - 3
NDA Sales Available Total Generic Sales Available
No 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* ****** ********* ****** ******* *********** ****-**, **. **.***/** & ***/**, ******* *******, ********** ******, ***** ***** ********, **********, ********* ******, ***** (***) ***
****** ***** ***** ******* *********** ****-*, ***-***, *** ********** **** **. *, ****. ******, *********, ****** ******* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.